Search 

Mesa Verde Venture Partners is a Venture Capital company founded in 2006. The firm is currently making investments out of its 2nd fund that had its first close in 2013. The firm makes primarily equity investment into seed and early stage rounds ranging from $500,000 to $1 million initially and up to $1.5 million over the lifetime of the investment. The firm is focused on companies located in the Southwestern United States although they are open to review companies from throughout the US. The firm could make as many as 3 new investments over the next 6-9 months.

Mid Atlantic Bio Angels (MABA) founded in 212 is an angel investor group based in the New York City area which focuses exclusively on new and emerging life science companies. The group places no geographical restrictions or requirements for presenting companies as long as meaningful and effective post-investment monitoring of these companies can be achieved, MABA has considered opportunities in Europe and Israel as well as across the USA and Canada. Since the members are investing their own capital the investment size is highly flexible and will depend on the financial needs of the company. The capital structure is typically in preferred stocks or convertible notes in qualified cases. The group prefers to invest in companies with valuations of less than $5M. As MABA prefers opportunities that can be entirely angel-financed MABA generally requires that companies can achieve exit with $15 million capital or under (generally after raising a Series B round but no further rounds).

MP Healthcare Ventures is the corporate venture arm of Mitsubishi Tanabe Pharma founded in 2006 and based in Boston Massachusetts. The firm is looking to provide equity capital to seed and venture stage companies in the life science space. The firm is looking to provide companies with $5 million over the lifetime of the investment and plans on making 2-3 investments over the next year. The firm will invest in companies located anywhere around the world.

The Office of Translational Alliances and Coordination (OTAC) at the National Heart, Lung, and Blood Institute supports the development of innovative biomedical products to address unmet medical needs in the heart, lung, blood and sleep fields.  OTAC is home to the NHLBI's small business programs (SBIR and STTR) and the NIH Centers for Accelerated Innovations.

The NHLBI's SBIR and STTR programs comprise one of the largest sources of early-stage capital for U.S. small business, acting as engines of innovation for developing and commercializing novel technologies and products that aid in the prevention, diagnosis, and treatment of heart, lung, blood, and sleep diseases and disorders. The NHLBI provides grant and contract funding opportunities and resources to support small businesses performing research and development on technologies related to the mission of NHLBI. With an annual budget of $85M, the NHLBI funds about 200 companies each year through the Institute's small business programs.

The NIH Centers for Accelerated Innovations accelerate translation of scientific discovery into commercial products that improve health for patients. This unique public-private partnership is changing the way discoveries with scientific and commercial potential are identified and developed.

Neurodyn Inc. (neurodyn.ca) is a Canadian biotechnology company using a portfolio approach to identifying, validating and developing natural bioactives into both prescription drugs and natural products for the early treatment of Alzheimer's Disease, Parkinson's Disease and other neurodegernative disorders. 

Memogain® is a patented pro-drug of an existing major Alzheimer's cognition enhancement drug, offering improved side effect profile and increased bioavailability. Initial Phase 1A results have been positive, showing no significant side effects and improved working memory in young and elderly volunteers. Memogain may qualify for a new US FDA accelterated pathway or Eu equivalent.

Cerbella™ is a treatment for early stage Parkinson's disease which has demonstrated in-vivo pre-clinical efficacy in acute models as well as Neurodyn's proprietary chronic model of Parkinson's disease. A product is expected to launch in Canada, USA or other countries in 2015.

NeuroPro® is a professionally-oriented supplement launched in October 2013, designed for neuroprotection and bansed on 5 years of animal model research.

Nerve Pain Treatment (PN34) is a rare first-in-class neuromodulator, being prepared for a topical orphan status nerve paincondition, with clinical trials to begin in 2015.

Progranulin (ND602) is a novel therapeutic demonstrating in-vivo pre-clinical efficacy in ALS, PD< Alzheimer's disease and Spinal Muscular Atrophy. The company is in its third year of collaboration (late stage pre-clinical evaluation) with the Michael J. Fox Foundation.

NuvOx Pharma is developing a series of biologics that increase tissue oxygenation. The company's first market will be in oncology, where increased tumor oxygenation increases the response of tumors to radiation therapy. The company recently started a Phase 1b clinical trial in Glioblastoma Multiforme, and is raising a $2.5 million Series A to complete this trial. Afterwards it will seek partners for a Phase 2b in Glioblastoma, and Phase 1b trials in lung cancer and other oncology indications. After growing to a critical mass in oncology, the company will seek to become standard treatment to increase tissue oxygenation for patients suffering from heart attack, stroke, hemorrhaggic shock, and traumatic brain injury.